Exane Derivatives’s Coresite Realty Corporation COR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,002
Closed -$126K 979
2020
Q4
$126K Sell
1,002
-56
-5% -$6.95K 0.04% 367
2020
Q3
$126K Buy
1,058
+28
+3% +$3.41K 0.04% 267
2020
Q2
$125K Buy
1,030
+1,025
+20,500% +$123K 0.03% 264
2020
Q1
$579 Hold
5
﹤0.01% 584
2019
Q4
$578 Sell
5
-86
-95% -$9.94K ﹤0.01% 604
2019
Q3
$11.1K Buy
91
+50
+122% +$5.73K ﹤0.01% 425
2019
Q2
$4.72K Buy
+41
New +$4.65K ﹤0.01% 477
2018
Q3
Sell
-1
Closed -$112 732
2018
Q2
$112 Sell
1
-3,060
-100% -$323K ﹤0.01% 609
2018
Q1
$312K Sell
3,061
-972
-24% -$99.5K 0.06% 190
2017
Q4
$459K Sell
4,033
-1,607
-28% -$183K 0.08% 170
2017
Q3
$631K Sell
5,640
-573
-9% -$63K 0.12% 123
2017
Q2
$643K Sell
6,213
-1,667
-21% -$167K 0.14% 123
2017
Q1
$709K Sell
7,880
-2,117
-21% -$184K 0.16% 108
2016
Q4
$793K Buy
9,997
+109
+1% +$8.02K 0.16% 103
2016
Q3
$732K Buy
9,888
+4,893
+98% +$397K 0.11% 127
2016
Q2
$443K Buy
4,995
+4,303
+622% +$332K 0.07% 137
2016
Q1
$48.4K Buy
+692
New +$43.4K 0.01% 315

Other funds holding COR

Exane Derivatives's COR Position: Q1 2021 in Review

Exane Derivatives sold out of Coresite Realty Corporation (COR) in Q1 2021, closing a stake of 1,002 shares — an estimated $126K sold.

Exane Derivatives first reported a position in COR in Q1 2016 and held it in 17 quarters. The position peaked at $793K in Q4 2016. 364 funds tracked by Wall St. Rank hold COR as of Q1 2021.

  • Exane Derivatives reported no remaining Coresite Realty Corporation position as of Q1 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,002 Coresite Realty Corporation shares in Q1 2021, an estimated $126K.
  • Exane Derivatives first reported a position in Coresite Realty Corporation in Q1 2016 and held it in 17 quarters.
  • Exane Derivatives's Coresite Realty Corporation position peaked at $793K in Q4 2016.
  • 364 funds tracked by Wall St. Rank held Coresite Realty Corporation as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.